{
    "root": "d1afd534-ca74-462d-9cbb-03e54547cd9a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "RIVAROXABAN",
    "value": "20250517",
    "ingredients": [
        {
            "name": "RIVAROXABAN",
            "code": "9NDF7JZ4M3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68579"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "D&C YELLOW NO. 10 ALUMINUM LAKE",
            "code": "CQ3XH3DET6"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        }
    ],
    "indications": {
        "text": "rivaroxaban tablets factor xa inhibitor indicated : reduce risk major cardiovascular events patients coronary artery disease ( cad ) ( 1.7 ) reduce risk major thrombotic vascular events patients peripheral artery disease ( pad ) , including patients recent lower extremity revascularization due symptomatic pad ( 1.8 )",
        "doid_entities": [
            {
                "text": "coronary artery disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "artery disease (DOID:0050828)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050828"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "peripheral artery disease (DOID:0050830)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050830"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "cad pad : 2.5 mg orally twice daily without food , combination aspirin ( 75-100 mg ) daily ( 2.1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "rivaroxaban tablets , usp available strengths packages listed : 2.5 mg tablets : yellow color , round shaped , film coated tablets , debossed \u201c \u201d one side \u201c 2.5 \u201d side . ndc 31722-496-60 bottle containing 60 tablets ndc 31722-496-18 bottle containing 180 tablets storage tablets : store room temperature 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . keep reach children .",
    "adverseReactions": "rivaroxaban tablets contraindicated patients : active pathological bleeding [ ( 5.2 ) ] severe hypersensitivity reaction rivaroxaban tablets ( e.g . , anaphylactic ) [ ( 6.2 ) ]",
    "indications_original": "Rivaroxaban tablets are a factor Xa inhibitor indicated: to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) (1.7) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD (1.8)",
    "contraindications_original": "CAD or PAD : 2.5 mg orally twice daily with or without food, in combination with aspirin (75-100 mg) once daily (2.1)",
    "warningsAndPrecautions_original": "Rivaroxaban tablets, USP are available in the strengths and packages listed below:\n                  \n                     2.5 mg tablets: Yellow color, round shaped, film coated tablets, debossed with \u201cT\u201d on one side and \u201c2.5\u201d on the other side.\n                  \n                  NDC 31722-496-60 Bottle containing 60 tablets\n                  NDC 31722-496-18 Bottle containing 180 tablets\n                  Storage of tablets:\n                  Store at room temperature between 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].\n                  Keep out of the reach of children.",
    "adverseReactions_original": "Rivaroxaban tablets are contraindicated in patients with:\n                  \n                     active pathological bleeding [see Warnings and Precautions (5.2)] \n                     \n                     severe hypersensitivity reaction to rivaroxaban tablets (e.g., anaphylactic reactions) [see Adverse Reactions (6.2)]",
    "drug": [
        {
            "name": "RIVAROXABAN",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68579"
        }
    ]
}